DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,331,289 B1 Klaveness Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,331,289 B1 Klaveness Et Al USOO6331289B1 (12) United States Patent (10) Patent No.: US 6,331,289 B1 Klaveness et al. (45) Date of Patent: Dec. 18, 2001 (54) TARGETED DIAGNOSTIC/THERAPEUTIC 5,716,594 2/1998 Elmaleh et al. .................... 424/1.41 AGENTS HAVING MORE THAN ONE 5,733,572 3/1998 Unger et al. ......................... 424/450 DIFFERENT VECTORS 5,780,010 7/1998 Lanza et al. ... 424/9.32 5,846,517 12/1998 Unger ........... ... 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Anders 5,849,727 12/1998 Porter et al. ......................... 514/156 Høgset; Helge Tolleshaug, Alan 5,910,300 6/1999 Tournier et al. .................... 424/9.34 Cuthbertson; Lars Hoff, Klaus Bryn; 6.245,318 6/2001 Klibanov et al. ................... 424/9.52 Halldis Hellebust; Magne Solbakken, FOREIGN PATENT DOCUMENTS all of Olso (NO) 2 145 SOS 4/1994 (CA). 19 626 530 7/1996 (DE). (73) Assignee: Nycomed Imaging AS, Oslo (NO) O 727 225 8/1996 (EP). WO 93/20802 10/1993 (WO). * Y NotOtice: Subjubject to anyy disclaimer,disclai theh term off thisthi WO 94/07539 4/1994 (WO). patent is extended or adjusted under 35 WO 94/28873 12/1994 (WO). U.S.C. 154(b) by 0 days. WO 94/28874 12/1994 (WO). WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). (21) Appl. No.: 08/959,206 WO95/07072 3/1995 (WO). (22) Filed: Oct. 28, 1997 WO95/15118 6/1995 (WO). WO 96/39149 12/1996 (WO). Related U.S. Application Data WO 96/40277 12/1996 (WO). (60) Provisional application No. 60/049.263, filed on Jun. 7, WO 96/40285 12/1996 (WO). 1997, provisional application No. 60/049.264, filed on Jun. WO 96/41647 12/1996 (WO). 6, 1997, and provisional application No. 60/049.266, filed WO 97/23855 7/1997 (WO). on Jun. 7, 1997. WO 97/33474 9/1997 (WO). WO 97/41898 11/1997 (WO). (30) Foreign Application Priority Data WO 98/OO172 1/1998 (WO). Oct. 28, 1996 (GB) .................................................. 9622366 WO 98/04293 2/1998 (WO). Oct. 28, 1996 (GB) ... ... 9622369 WO 98/19705 5/1998 (WO). Feb. 4, 1997 (GB) ... ... 97.02195 WO 98/20856 5/1998 (WO). Apr. 24, 1997 (GB) ... ... 9708265 WO 98/42384 10/1998 (WO). Jun. 6, 1997 (GB) ... ... 9711837 OTHER PUBLICATIONS Jun. 6, 1997 (GB) .................................................. 9711839 Worthington Enzyme Manual, Worthington Biochemical (51) Int. Cl. ............................. A61B 8/00; A61K 51/00; Corporation, 1972. A61K 9/127 U.S. application No. 08/640,464, Unger, filed May 1, 1996. (52) U.S. Cl. ......................... 424/9.52; 424/1.21; 424/9.4; U.S. application No. 08/660,032, Unger, filed Jun. 6, 1996. 424/9.6; 424/450 U.S. application No. 08/712,173, Unger, filed Sep. 11, 1996. (58) Field of Search .................................. 424/9.52, 9.51, Medline database extract No. XP-002063692, 1997. 424/9.5, 450, 489, 498, 499, 502, 1.21, Biosis database extract No. XP-002063693, Nov. 1997. 9.4, 9.6, 9.1; 530/300, 324, 326, 327: 514/14 Medline database extract No. KP-002064110, 1997. Muzykantov et al., J. Nuclear Medicine, 35(8): 1358–1365 (56) References Cited (1994). U.S. PATENT DOCUMENTS Klibanov et al., Acta Radiologica, 38(Supp. 412): 113-120 (1997). 4,927,916 5/1990 Matsueda ............................. 530/387 5,013,556 5/1991 Woodle et al. ...................... 424/450 * cited by examiner 5,154,924 10/1992 Friden ........ 424/85.91 5,198.424 3/1993 McEver .................................. 514/13 Primary Examiner Michael G. Hartley 5,356,633 10/1994 Woodle et al. ... 424/450 (74) Attorney, Agent, or Firm-Bacon & Thomas 5,362.478 11/1994 Desai et al. .............................. 424/9 (57) ABSTRACT 5,498,421 3/1996 Grinstaff et al. ..................... 424/450 5,505,932 4/1996 Grinstaff et al. ... ... 424/9.3 Targetable diagnostic and/or therapeutically active agents, 5,534.241 7/1996 Torchillin et al. ... 424/9.321 e.g. ultrasound contrast agents, comprising a Suspension in 5,612,057 3/1997 Lanza et al. ......................... 424/450 an aqueous carrier liquid of a reporter comprising gas 5,632,986 5/1997 Tait et al. ....... ... 424/94.64 5,643,553 7/1997 Schneider et al. ... 424/9.52 containing or gas-generating material, Said agent being 5,650,156 7/1997 Grinstaff et al. ... ... 424/400 capable of forming at least two types of binding pairs with 5,656.211 8/1997 Unger et al. ....... ... 264/4.1 a target. 5,665,383 9/1997 Grinstaff et al. ... 424/450 5,690,907 11/1997 Lanza et al. .......................... 424/9.5 22 Claims, 1 Drawing Sheet U.S. Patent Dec. 18, 2001 US 6,331,289 B1 256 Gm: 15.62 CW. 34.39 144-1023) 18430 (92.2/) FITClog F. G. 1. US 6,331,289 B1 1 2 TARGETED DIAGNOSTIC/THERAPEUTIC Surfactant material but rather that this is incorporated in AGENTS HAVING MORE THAN ONE liquid-filled liposomes which stabilise the microbubbles. It DIFFERENT VECTORS will be appreciated that lamellar or laminar Surfactant mate rial Such as phospholipids present in Such liposomes will This application claims benefit of the filing dates under 5 inevitably be present in the form of one or more lipid 35 USC 119(e) of U.S. provisional applications 60/049.263 bilayers with the lipophilic tails “back-to-back” and the and 049,264 filed on Jun. 6, 1997 and 60/049,266 filed on hydrophilic heads both inside and outside (see e.g. Jun. 7, 1997. Schneider, M. on "Liposomes as drug carriers: 10 years of It is well known that ultraSonic imaging comprises a research” in Drug targeting, Nyon, Switzerland, 3-5 Octo potentially valuable diagnostic tool, for example in Studies ber 1984, Buri, P. and Gumma, A. (Ed), Elsevier, Amsterdam of the vascular System, particularly in cardiography, and of 1984). tissue microvasculature. A variety of contrast agents has EP-A-0727225 describes targeted ultrasound contrast been proposed to enhance the acoustic images So obtained, agents in which the reporter comprises a chemical having a including Suspensions of Solid particles, emulsified liquid Sufficient vapour pressure Such that a proportion of it is a gas droplets, gas bubbles and encapsulated gases or liquids. It is 15 at the body temperature of the subject. This chemical is generally accepted that low density contrast agents which asSociated with a Surfactant or albumin carrier which are easily compressible are particularly efficient in terms of includes a protein-, peptide- or carbohydrate-based cell the acoustic backScatter they generate, and considerable adhesion molecule ligand as vector. The receptor moieties in interest has therefore been shown in the preparation of Such contrast agents correspond to the phase shift colloid gas-containing and gas-generating Systems. systems described in WO-A-9416739; it is now recognised Gas-containing contrast media are also known to be that administration of Such phase shift colloids may lead to effective in magnetic resonance (MR) imaging, e.g. as generation of microbubbles which grow uncontrollably, susceptibility contrast agents which will act to reduce MR possibly to the extent where they cause potentially danger Signal intensity. Oxygen-containing contrast media also rep ouS embolisation of, for example, the myocardial vascula resent potentially useful paramagnetic MR contrast agents. 25 ture and brain (see e.g. Schwarz, Advances in Echo-Contrast Furthermore, in the field of X-ray imaging it has been 1994(3)], pp. 48–49). observed that gases Such as carbon dioxide may be used as WO-A-9320802 proposes that tissue-specific ultrasonic negative oral contrast agents or intravascular contrast image enhancement may be achieved using acoustically agents. reflective oligolamellar liposomes conjugated to tissue The use of radioactive gases, e.g. radioactive isotopes of Specific ligands Such as antibodies, peptides, lectins etc. The inert gases Such as Xenon, has also been proposed in liposomes are deliberately chosen to be devoid of gas and So Scintigraphy, for example for blood pool imaging. will not have the advantageous echogenic properties of Targeted ultrasound contrast agents may be regarded as gas-based ultrasound contrast agents. Further references to comprising (i) a reporter moiety capable of interacting with this technology, e.g. in targeting to fibrin, thrombi and ultrasound irradiation to generate a detectable signal; (ii) one 35 atherosclerotic areas are found in publications by or more vectors having affinity for particular target Sites Alkanonyuksel, H. et al. in J. Pharm. Sci. (1996) 85(5), and/or structures within the body, e.g. for Specific cells or 486-490, J. Am. Coll. Cardiol. (1996)27(2) Suppl A, 298A; areas of pathology; and (iii) one or more linkers connecting and Circulation, 68 Sci. Sessions, Anaheim 13-16 Novem said reporter and vector(s), in the event that these are not ber 1995. directly joined. 40 There is also a number of publications concerning ultra The molecules and/or structure to which the contrast Sound contrast agents which refer in passing to possible use agent is intended to bind will hereinafter be referred to as the of monoclonal antibodies as vectors without giving Signifi target. In order to obtain specific imaging of a Selected cant practical detail and/or to reporters comprising materials region/structure in the body the target must be present and which may be taken up by the reticuloendothelial System available in this region/structure. Ideally it will be expressed 45 and thereby permit image enhancement of organs Such as the only in the region of interest, but usually will also be present liver-see, for example WO-A-9300933, WO-A-94.01140, at other locations in the body, creating possible background WO-A-9408.627, WO-A-9428874, U.S.
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • IIIHIIIUSOO5304377A Unitedo States Patent 19 (11) Patent Number: 5,304,377 Yamada Et Al
    IIIHIIIUSOO5304377A UnitedO States Patent 19 (11) Patent Number: 5,304,377 Yamada et al. (45) Date of Patent: Apr. 19, 1994 54 PROLONGED RELEASE PREPARATION 4,954,298 9/1990 Yamamoto et al. ................. 264/4.6 AND POLYMERS THEREOF 4,962,091 10/1990 Eppstein et al. ........................ 514/2 75) Inventors: Minoru Yamada; Seiko Ishiguro, both 5,061,492 10/1991 Okada et al. ........................ 424/423 Otokuni, all of Japan 0052510 11/1981 European Pat. Off. 73) Assignee: Sherical4. industries, Ltd., O256726O190833 7/19871/1986 European Pat. Off. a, Japan 0263490 10/1987 European Pat. Off. (21) Appl. No.: 986,299 0281482 3/1988 European Pat. Off. 035.0246 7/1989 European Pat. Off. 22 Filed: Dec. 7, 1992 2-212436 8/1990 Japan. Related U.S. Application Data OTHER PUBLICATIONS 63) continuation of ser. No. 777,170, oct. 16, 1991, aban- Chemical Abstracts, vol. 114/No. 6 (Feb. 11, 1991); doned. Columbus, Ohio; Abstract No. 49615R. 30 Foreign Application Priority Data Primary Ent, S. Sir Mueller & Oct. 16, 1990 (JP) Japan .................................. 2-278037 story Agent, or Firm-Wegner, Cantor, Mueller Aug. 28, 1991 JP Japan .................................. 3.217045 51 Int, Cl. ......................... A61K 9/22; A61K 9/52; ' ABSTRACT A61K 31/74 A polymer for a prolonged release preparation which 52 U.S. Cl. ................................. 424/426; 424/78.08; comprises 424/78.37; 424/434; 424/457; 424/468; (A) a polylactic acid and 424/486; 424/497; 525/450, 514/2 (B) a copolymer of glycolic acid and a hydroxycar 58) Field of Search .................. 424/426, 78.08, 78.37, boxylic acid of general formula 424/434, 457, 468, 486, 497; 525/450; 514/2 (56) References Cited R U.S.
    [Show full text]
  • ANNNNNNNNNNNNNNNNNNNN 100A 006 Left Eye Input Right Eye Input
    US 20190175049A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0175049 A1 Welling ( 43 ) Pub . Date : Jun . 13 , 2019 ( 54 ) TECHNIQUES FOR ANALYZING (52 ) U . S . CI. NON -VERBAL MARKERS OF CONDITIONS CPC . .. A61B 5 /04842 (2013 . 01 ) ; A61B 5 / 7289 USING ELECTROPHYSIOLOGICAL DATA (2013 . 01) ; A61B 5 /0478 ( 2013 .01 ) ; A61B 5 /7225 ( 2013. 01 ) ; G06N 20 / 10 (2019 .01 ) (71 ) Applicant: Massachusetts Institute of Technology , Cambridge , MA (US ) ( 57 ) ABSTRACT (72 ) Inventor : Caroline Welling, Hanover, NH (US ) Embodiments related to analyzing brain activity of a subject to identify signs associated with binocular rivalry . Sensed ( 21 ) Appl. No. : 16 / 206, 639 electrical activity of a subject' s brain is received over a time period while the subject is exposed to a visual stimulus. The ( 22 ) Filed : Nov. 30 , 2018 sensed electrical activity comprises a first frequency band Related U . S . Application Data associated with a first frequency of a first image presented to the subject ' s left eye , a second frequency band associated (60 ) Provisional application No .62 / 593 , 535, filed on Dec . with a second frequency of a second image presented to the 1 , 2017 subject ' s right eye . A set of events in the time period is determined based on the frequency bands, wherein an event Publication Classification is associated with a change from a previous perceptual event (51 ) Int. Ci. to a new perceptual event. A metric for the subject is A61B 5 /0484 ( 2006 .01 ) determined based on the set of events . The metric is ana A61B 5 /00 ( 2006 .01 ) lyzed to determine whether the subject exhibits signs asso GO6N 20 / 10 (2006 .01 ) ciated with a condition that is associated with binocular A61B 5 /0478 ( 2006 .01 ) rivalry .
    [Show full text]
  • Identificación Computacional De Nuevos Compuestos Líderes Con Actividad Analgésica
    IDENTIFICACIÓN COMPUTACIONAL DE NUEVOS COMPUESTOS LÍDERES CON ACTIVIDAD ANALGÉSICA Autor: Earmin Shangoo. Tutores: Dr. Yovani Marrero Ponce MSc. Arelys López Sacerio Lic. Gerardo Maikel Casañola Martín “Año 49 de la Revolución Cubana” Curso 2006-2007 PENSAMIENTO “For all flesh is as grass, and all the glory of man as the flower of grass. The grass withereth, and the flower thereof falleth away: But the word of the Lord endureth for ever.” 1 Peter1:24,25. “Todo carne es como hierba y toda la gloria del hombre como flor de la hierba; la hierba se seca y la flor se cae, mas la palabra del Señor permanece para siempre.” 1 Pedro 1:24,25. DEDICATORIA For all my friends and family, especially my daughter, Naarah Melani Nerissa Athanase and my husband, Jeremiah Wayn Athanase, with love and admiration. “I have fought a good fight, I have finished my course…” 2Tim 4:7. Con mucho cariño y admiración, a todas mis amigos y mi familia en particular a mi hija, Naarah Melani Nerissa Athanase y mi esposo, Jeremiah Wayn Athanase. “He peleada la buena batalla, he acabado la carrera…” 2Ti 4:7 AGRADECIMIENTOS For me it is an enormous pleasure to be able to express my sincere gratefulness to all those people that in one way or another has helped me to successfully culminate my studies and this work. I would especially like to thank God because without him I am nothing; to my family for their faith, support, love and patience; to my tutors especially Arelys for their attention, dedication and orientation during this work; to all the professors of the career that made possible with their patient, constant and opportune help my formation as a pharmaceutical professional; to my friends, in particular to Solange and Harun; to all thank you.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Genetically Modified Baculoviruses for Pest
    INSECT CONTROL BIOLOGICAL AND SYNTHETIC AGENTS This page intentionally left blank INSECT CONTROL BIOLOGICAL AND SYNTHETIC AGENTS EDITED BY LAWRENCE I. GILBERT SARJEET S. GILL Amsterdam • Boston • Heidelberg • London • New York • Oxford Paris • San Diego • San Francisco • Singapore • Sydney • Tokyo Academic Press is an imprint of Elsevier Academic Press, 32 Jamestown Road, London, NW1 7BU, UK 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA ª 2010 Elsevier B.V. All rights reserved The chapters first appeared in Comprehensive Molecular Insect Science, edited by Lawrence I. Gilbert, Kostas Iatrou, and Sarjeet S. Gill (Elsevier, B.V. 2005). All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publishers. Permissions may be sought directly from Elsevier’s Rights Department in Oxford, UK: phone (þ44) 1865 843830, fax (þ44) 1865 853333, e-mail [email protected]. Requests may also be completed on-line via the homepage (http://www.elsevier.com/locate/permissions). Library of Congress Cataloging-in-Publication Data Insect control : biological and synthetic agents / editors-in-chief: Lawrence I. Gilbert, Sarjeet S. Gill. – 1st ed. p. cm. Includes bibliographical references and index. ISBN 978-0-12-381449-4 (alk. paper) 1. Insect pests–Control. 2. Insecticides. I. Gilbert, Lawrence I. (Lawrence Irwin), 1929- II. Gill, Sarjeet S. SB931.I42 2010 632’.7–dc22 2010010547 A catalogue record for this book is available from the British Library ISBN 978-0-12-381449-4 Cover Images: (Top Left) Important pest insect targeted by neonicotinoid insecticides: Sweet-potato whitefly, Bemisia tabaci; (Top Right) Control (bottom) and tebufenozide intoxicated by ingestion (top) larvae of the white tussock moth, from Chapter 4; (Bottom) Mode of action of Cry1A toxins, from Addendum A7.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • 1 Liste Des 3000 Ingrédients Controversés Évités Par
    LISTE DES 3000 INGRÉDIENTS CONTROVERSÉS ÉVITÉS PAR MODERE 1 SOINS PERSONNELS Conformément au paradigme des ingrédients de MODERE, la compagnie exclu une liste de plus de 3000 ingrédients controversés différents à éviter dans les formulations de ses produits. Chaque année, les chercheurs publient de nouvelles informations sur les ingrédients des produits. Modere convoque régulièrement son Scientific Advisory Board (Conseil Consultatif Scientifique) afin de : - réexaminer la science qui se cache derrière certains ingrédients et - donner des recommandations sur l'utilisation que Modere fait de ces ingrédients. Cependant, quand de nouveaux ingrédients sont ajoutés à sa liste, il est possible que certains éléments faisant partie de la large gamme de produits MODERE contiennent ces nouveaux ingrédients controversés. Ainsi, Modere doit entamer le processus de reformulation qui prend un certain temps à développer et à implémenter. Malheureusement, en raison de ces processus continus de découvertes, d'évaluations et de reformulations, MODERE ne sera respectera peut être pas toujours sa liste d'ingrédients controversés à 100%. Nous sommes cependant fiers de la position de leader que Modere occupe dans cette industrie, et nous sommes confiants que les produits Modere garantissent de manière jusqu'à présent inégalée la sécurité de nos consommateurs. Modere évite les formulations dans ses soins personnels avec des ingrédients tels que : (2-Isopropylpent.4-Enoyl) 2,2,6-Trimethyl-4-piperidyl 2-Methyl-m- urée (apronalide) benzoate (benzamine) phenylenediamine
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]